12 Best Diabetes Stocks To Buy Now

Published on November 26, 2023 at 3:11 pm by Faiq Zafar in Business, Hedge Funds, Industries, News

In this article, we shall discuss the 12 best diabetes stocks to buy now. To skip our detailed analysis of the global diabetes drugs industry in 2023, go directly and see 5 Best Diabetes Stocks to Buy Now.

Diabetes is a chronic metabolic disease which is normally characterized by high blood glucose levels, which tend to severely damage the heart, blood vessels, eyes, kidneys, and the nervous system. According to a report by Precedence Research, the global diabetes drug market size was valued at $61.9 billion in 2022 and is expected to hit $118 billion by 2032, growing at a CAGR of 6.67% during the forecast period 2022-2032. The market was predominantly controlled by the insulin segment of the diabetes industry, with the insulin segment to grow at a CAGR of more than 3% during the forecast period, owing to skyrocketing demand from people who suffer from Type-1 diabetes.

This rampant growth is catalyzed by certain drivers, one of them being an excessive sugar diet. Advancements in diabetes diagnosis devices like portable glucometers drive the diabetes market to post impressive growth figures. Furthermore, an increase in R&D for innovating diabetes treatments and market product approvals is a significant contributor to the market share growth for some of the best diabetes stocks to buy now like Abbott Laboratories (NYSE:ABT), Pfizer Inc. (NYSE:PFE), and Eli Lilly and Company (NYSE:LLY). Furthermore, technological innovation in diabetic treatment provides enormous opportunities for the diabetes sector. Innovation in technology, such as the introduction of high-end insulin pumps and pens, cause demand to surge and encourages leading manufacturers to direct greater investments in developing advanced products to secure significant market shares. According to a report by Bloomberg, more than 1.3 billion people globally are projected to by inflicted with diabetes by 2050, which in turn, is likely to cause demand for diabetes drugs to surge. The vast majority of this population is expected to have type-2 diabetes, which is the variant of the disease intricately interlinked with obesity. A report by McKinsey also highlights that the rampant growth in the fast food industry and innovations and evolutions in food delivery are a primary cause of obesity in many countries and are directly linked to a rise in diabetes. With food delivery becoming a global market valued at more than $150 million as of 2022, the outlook for global diabetes seems to be incredibly bleak. However, it provides huge upside potential for some of the best diabetes stocks to buy now. You can read more on the diabetes industry in our article 10 Best Ways to Prevent Type-2 Diabetes.

Digital Therapeutics in the Diabetes Industry: An Overview

As the burden of chronic diseases, like diabetes and obesity, exacerbate around the world and insert additional pressure on already dwindling economic and public health systems, these challenges have created a need for extensive and effective disease management solutions which are optimized and enabled via digital technologies. According to McKinsey, global health funding grew at an impressive rate of a little less than 80% over 2022 to reach more than $57.2 billion in 2023. Within this segment, funding for digital therapeutics has surged at a greater rate – up by more than 130% as compared to 2022 to reach a mammoth $8.9 billion in 2021. Hence, it becomes increasingly clearer that digital therapeutics can play an infinitely critical role in the management and even responsiveness to chronic diseases like diabetes. The article asserts that chronic diseases need to be dealt with not only by mere medication by also with regular monitoring and lifestyle changes, causing some of the best diabetes stocks to buy now like Abbott Laboratories (NYSE:ABT), Pfizer Inc. (NYSE:PFE), and Eli Lilly and Company (NYSE:LLY) to divert greater investments towards the production and development of digital therapeutic devices. These companies have understood that digital technologies can play a critical role in drastically facilitating disease management, primarily owing to the fact that more than 67% of the global population now has an unrestricted access to the internet, as per a report by Freedom House.

McKinsey sheds light upon four primary elements of impactful digital therapeutics solutions, one of them being regular monitoring, measurement and feedback through a connected medical device ecosystem. Technologies such as smart inhalers and continuous glucose monitors can alert patients and provide them with out-of-range readings. Secondly, the best diabetes stocks to buy now like Abbott Laboratories (NYSE:ABT), Pfizer Inc. (NYSE:PFE), and Eli Lilly and Company (NYSE:LLY) which have diverted significant focus on the development of their digital therapeutics portfolio must keep payers and providers within the information ecosystem, by opening the doors for payers to identify and reward good behavior on the part of the patient, and penalize poor adherence to health plans which are prescribed by providers. Furthermore, companies can also invest in the integration of gamified behavioral modification techniques by offering challenges and incentives to track compliance with health plans. Lastly a recent survey conducted by McKinsey discovered that more than 90 percent of healthcare leaders are of the view that patients prefer an integrated journey rather than point experiences. Companies can fulfill this desire by investing in digital health malls which include easy access to prescribed medications, health supplements, wellness products, and diagnostic kits.

Our Methodology

To compile our list of the 12 best diabetes stocks to buy now, we first made a list of the 30 largest diabetes companies in the world in terms of their market capitalization. Some companies are pure-play diabetes companies while others generate a significant portion of their annual revenue through diabetes drugs and devices. Then, we picked 12 stocks with strong fundamentals, positive analyst ratings, or a favorable hedge fund sentiment. The stocks have been ranked based on the number of hedge funds which hold stakes in them as of Q3 2023, from lowest to highest.

To read more on some of the emerging markets for diabetes companies, check out our article on the 30 Countries With The Highest Diabetes Per Capita.

Best Diabetes Stocks To Buy Now

12. Tandem Diabetes Care Inc. (NASDAQ:TNDM)

Hedge Fund Holdings: 17

Based in San Diego, California, Tandem Diabetes Care Inc. (NASDAQ:TNDM) is an American medical device manufacturer which focuses on the production and development of advanced medical technologies for the management of diabetes and specifically insulin infusion therapy. The company’s balance sheet is in good shape overall and management is fairly optimistic with respect to new product launches which are expected to drive sales growth and reduce losses. The company is executing on numerous near-term product launches whilst implementing scalable systems and processes to uphold global operations and leverage the company’s infrastructure. In Q3 2023, Tandem Diabetes Care Inc. (NASDAQ:TNDM) generated a total revenue of $185.6 million. The following is an excerpt from CEO John Sheridan’s statement from Tandem Diabetes Care’s (NASDAQ:TNDM) Q3 2023 earnings call transcript:

“Reflecting on our third quarter results, our overall performance was above our baseline expectations, primarily due to the U.S. market. Over the past few weeks, I have had an opportunity to attend some of our regional sales meetings across the United States and was excited and encouraged by my conversations. My first takeaway is that the t:slim X2 and with Control-IQ continues to be the best AID system available. This is also reflected in third-party research and our own customer satisfaction surveys. It’s evident in our low attrition and higher percentage of customers choosing to purchase a new t:slim X2 from Tandem after their warranty expires. My next takeaway is that overall competitive dynamics remain stable. Some products are newer than others, but the noise from the other AID offerings is in line with our expectations, and the diabetes community is learning more about what these products are and what they are not.”

11. Novartis AG (NYSE:NVS)

Hedge Fund Holdings: 26

Based in Basel, Switzerland, Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation and is one of the largest pharmaceutical companies in the world by revenue. The company was able to maintain hedge fund sentiment around its stock with 26 funds long the stock in both, Q2 and Q3 of 2023. In Q3 2023, Novartis AG (NYSE:NVS) generated an annual revenue of $12.1 billion. The company beat EPS estimates of $1.7 by $0.13, generating earnings of $1.83 per share in Q3 2023.

The stock is expected to experience a margin uplift in the near-term and post the Sandoz spinoff, Novartis AG (NYSE:NVS) has been able to drastically build upon its growth and overall profile. The biopharma business is doing remarkably well overall and owing to a substantial acquisition of high-growth products and pipeline potential, the company is incredibly well-positioned to generate impressive shareholder value in the coming years. Novartis AG (NYSE:NVS) has posted incredible growth in 2023, with an AA- credit rating from S&P. Furthermore, the stock as a 3.5% dividend yield and a mid to upper-single-digit annual earnings growth, making it one of the best diabetes stocks to buy now for investors interested in dividends.

10. Sanofi SA (NYSE:SNY)

Hedge Fund Holdings: 29

Headquartered in Paris, France, Sanofi SA (NYSE:SNY) is a French multinational pharmaceutical and healthcare company which focuses on the research and development, manufacturing, and marketing of pharmacological products, primarily catering to the prescription market. In Q3 2023, Sanofi SA (NYSE:SNY) posted an EPS of $2.77, beating estimates of $2.27 by $0.5.

On November 15, Berenberg Bank raised the price target on Sanofi SA (NYSE:SNY) from $55 to $56, and maintained a Buy rating on the shares. With reports of the company preparing for a separation of its consumer health business doing the rounds, ADRs for Sanofi SA (NYSE:SNY) ticked up briefly. The company expects 2023 business EPS to grow mid single-digit at CER, not considering any unforeseen major events. The continued impressive performance of the company’s Dupixent drug and the excitement surrounding the product launch of Beyfortus are expected to continue driving growth for the stock in 2024 and point towards a highly strategic execution towards sustainable growth on the backs of innovative medications.

9. Insulet Corporation (NASDAQ:PODD)

Hedge Fund Holdings: 44

Based in Massachusetts, Insulet Corp. (NASDAQ:PODD) is an American diabetes device manufacturer which focuses on the production and development of insulin delivery systems. Hedge fund sentiment around Insulet Corp. (NASDAQ:PODD) increased in Q3 2023, with 44 hedge funds having stakes in the stock, up from 39 a quarter ago. The company generated earnings of $0.71 per share, beating estimates of $0.4 by $0.31.

On November 18, BofA slashed the price target on Insulet Corp. (NASDAQ:PODD) to $180 from $295, and maintained a Buy rating on the shares. The company’s third quarter results far exceeded expectations with global Omnipod growth of more than 27%. Total company grew more than 25% and as the result, the company raised guidance for all of 2023. The company is seeing robust operating momentum and although there was an initial dip in stock price after the rapid growth of weight loss therapies by other companies which are expected to disrupt the diabetes market as a whole, the stock jumped by more than 10% after the company reported strong sales of its Omnipod insulin pumps and raised guidance significantly, putting up a strong resistance to investor scrutiny that GLP-1 weight loss drugs might chip away at the sales of diabetes management devices.

8. AstraZeneca plc (NYSE:AZN)

Hedge Fund Holdings: 49

Based in Cambridge, England, AstraZeneca plc (NYSE:AZN) is an Anglo-Swedish multinational pharmaceutical and biotechnology enterprise which focuses on developing a portfolio of products geared towards treating oncology, infection and diabetes. On November 22, Berenberg Bank raised the price target on AstraZeneca plc (NYSE:AZN) to $78 from $76, and maintained a Buy rating on the shares. The analyst maintained that AstraZeneca plc (NYSE:AZN) is one of the best diabetes stocks to buy now in terms of five-year share price growth. The company’s product portfolio is much more diversified than its competitors, with oncology division revenues 17% higher year-on-year in 1H23.

Hedge fund sentiment around AstraZeneca plc (NYSE:AZN) has skyrocketed in Q3 2023, with 49 funds long the stock, up from 41 funds in the preceding quarter. In the third quarter of 2023, the company posted earnings of $0.87 per share, beating estimates of $0.84 by $0.03. Furthermore, AstraZeneca plc (NYSE:AZN) generated a quarterly revenue of $11.4 billion in Q3 2023.

7. Novo Nordisk AS (NYSE:NVO)

Hedge Fund Holdings: 51

Based in Bagsværd, Denmark, Novo Nordisk AS (NYSE:NVO) is a Danish multinational pharmaceutical company which manufactures and markets pharmaceutical products and services, primarily focusing on diabetes care medications and devices. In Q3 2023, the company met EPS expectations, generating earnings of $0.73 per share. Investor interest around Novo Nordisk AS (NYSE:NVO) surged in Q3 2023, with 51 hedge funds long the stock. This was significantly up from Q2 2023, where 43 funds held stakes in Novo Nordisk AS (NYSE:NVO).

On November 13, Deutsche Bank analyst Emmanuel Papadakis conferred a Buy rating upon the stock, and maintained the price target at $113.7. The company has surpassed Nestle as the largest developed-market stock outside of the United States, shedding light upon the resounding success of the GLP-1 drug segment. Furthermore, Novo Nordisk AS (NYSE:NVO) posted robust Q3 2023 results with a 29% year-over-year increase in revenue and as a result, boosted its full-year outlook substantially. Papadakis further expects significant earnings growth for Novo Nordisk in 2023, and maintains that the low stock price currently presents an excellent entry-point for investors.

6. Medtronic plc (NYSE:MDT)

Hedge Fund Holdings: 59

Headquartered in Minneapolis, Minnesota, Medtronic plc (NYSE:MDT) is an American medical device company which focuses on the development and manufacture of healthcare technologies and therapies. On November 22, Morgan Stanley lowered the price target on Medtronic plc (NYSE:MDT) to $98 from $104, and maintained an Overweight rating on the shares. The company posted incredibly impressive Q3 2023 results, generating earnings of $1.25 per share, beating estimates of $1.18 by $0.07. Furthermore, the company generated a revenue of $8 billion, an increase of 5.4% year-over-year. Consequently, Medtronic plc (NYSE:MDT) elevated its FY24 organic revenue growth guidance to 4.75%, up from 4.5%. The companies revenues are adequately dispersed across various different segments, and owing to further product launches and the adoption of integrated solutions in the pipeline, the company expects further growth in 2024. Furthermore, Medtronic plc (NYSE:MDT) has a dividend yield of 4%, making it one of the best diabetes stocks to buy now for investors interested in generating a steady income from the stock.

Click here to continue reading and see 5 Best Diabetes Stocks to Buy Now.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up